A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)
Ontology highlight
ABSTRACT: This randomized, multi-center, active-controlled, open-label, parallel-group study will investigate the efficacy and safety of biomarker-driven maintenance treatment for first-line mCRC. Participants with mCRC are eligible for entry and cannot have received any prior chemotherapy in the metastatic setting. The entire study duration is anticipated to be approximately 7.5 years.
DISEASE(S): Metastatic Colorectal Cancer,Colorectal Cancer,Colorectal Neoplasms,Carcinoma Colorettale Metastatico
PROVIDER: 2178309 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA